抗IL-9抗体治疗肝癌恶性腹水的疗效及其机制研究

发布时间：2018-12-13 10:38

【摘要】：目的:探索抗IL-9抗体治疗小鼠肝癌恶性腹水(MA)的疗效及作用机制。方法:应用小鼠H22细胞系建立小鼠MA模型,造模24 h后将45只小鼠随机分成实验组、阴性对照组和空白对照组,每组15只。实验组给予腹腔注射抗IL-9抗体,阴性对照组给予注射同型Ig G抗体,空白对照组给予注射生理盐水,隔天1次,共注射5次。每次注射前均称量各组小鼠体重,并观察小鼠日常活动状态。末次用药结束24 h后每组随机处死5只小鼠,测量MA体积,收集MA上清,采用ELISA法检测MA中VEGF、MMP-2、IL-9、IFN-γ表达水平。其余小鼠观察其生存时间。结果:干预后实验组、阴性对照组和空白对照组小鼠的MA体积分别为(6.70±1.52)ml、(10.28±1.75)ml、(10.36±2.30)ml,与空白对照组和阴性对照组相比,实验组小鼠MA体积明显减少,差异有统计学意义(P0.05)。实验组小鼠平均生存时间为(17.2±2.1)d,显著长于阴性对照组(14.5±1.2)d和空白对照组(14.8±1.4)d(P0.05);与空白对照组和阴性对照组相比,实验组小鼠MA中VEGF水平显著降低,差异有统计学意义(P0.05),与阴性对照组相比,实验组小鼠MA中IL-9水平显著降低,差异有统计学意义(P0.05);但三组间MMP-2、IFN-γ水平比较差异无统计学意义(P0.05)。结论:腹腔注射抗IL-9抗体可以有效地抑制H22细胞荷瘤小鼠MA的产生,延长其生存时间,该作用可能是通过抑制MA中VEGF、IL-9的表达而实现。
[Abstract]:Objective: to explore the effect and mechanism of anti-IL-9 antibody in the treatment of murine hepatocellular carcinoma (HCC) malignant ascites (MA). Methods: mouse MA model was established by mouse H22 cell line. After 24 hours, 45 mice were randomly divided into experimental group, negative control group and blank control group with 15 mice in each group. The experimental group was intraperitoneally injected with anti IL-9 antibody, the negative control group was injected with the same type of Ig G antibody, and the blank control group was injected with normal saline once every other day for 5 times. The body weight of each group was measured before each injection, and the state of daily activities of the mice was observed. Five mice in each group were randomly killed 24 hours after the last administration, the volume of MA was measured, the supernatant of MA was collected, and the expression of VEGF,MMP-2,IL-9,IFN- 纬 in MA was detected by ELISA method. The remaining mice were observed for their survival time. Results: the MA volumes of the experimental group, the negative control group and the blank control group were (6.70 卤1.52) ml, (10.28 卤1.75) ml, (10.36 卤2.30) ml, respectively, compared with the blank control group and the negative control group. The volume of MA in experimental group decreased significantly (P0.05). The average survival time of the experimental group was (17.2 卤2.1) days, which was significantly longer than that of the negative control group (14.5 卤1.2) days and the blank control group (14.8 卤1.4) d (P0.05). Compared with the blank control group and the negative control group, the VEGF level in the MA in the experimental group was significantly lower than that in the negative control group (P0.05), and the IL-9 level in the MA in the experimental group was significantly lower than that in the negative control group. The difference was statistically significant (P0.05). However, there was no significant difference in MMP-2,IFN- 纬 levels among the three groups (P0.05). Conclusion: intraperitoneal injection of anti IL-9 antibody can effectively inhibit the production of MA and prolong the survival time of mice bearing tumor of H22 cell. This effect may be achieved by inhibiting the expression of VEGF,IL-9 in MA.
【作者单位】：广西医科大学第一附属医院消化内科;
【基金】：国家自然科学基金(No.31560257;31360221)资助
【分类号】：R735.7

【相似文献】